FTSE 100 slips from best levels but Hikma benefits from US asthma drug news
The UK blue chip index pares gains but housebuilders supported by latest government figures
FTSE up 22 points
House prices surge most since 2014
11.49am: Hikma higher, Just Eat drops
Leading shares may be losing some of their early lustre but investors are buying into Hikma Pharmaceuticals PLC (LON:HIK).
The company is the biggest riser in the blue chip index, up 61p or 2.57% at 2439p after it said it had resumed the launch in the US of its generic version of GlaxoSmithKline's Advair Diskus treatment for asthma and pulmonary diseases.